AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$RGEN

Loeillot Olivier sold $504K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 3,035 shares of REPLIGEN CORP (RGEN) at $165.90 ($0.50M total) on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Sep 8, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RGEN
Bearish
medium confidence
Mentioned
$RGEN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENBearishLow
01

Why it matters

The CEO's sale reduces his ownership, which may be interpreted as a negative signal, but the modest amount limits market reaction.

02

Market read

Primary disclosure of a CEO insider sale; modest size suggests limited trading impact but warrants monitoring.

03

What to watch

Potential 10b5‑1 plan execution and any upcoming earnings or clinical trial news could offset the sale impact.

Relevance 4/10Novelty 5/10Timing: post‑market filing on Sep 4 2026

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$RGENBearishMedium confidence
Context

CEO Loeillot Olivier sold 3,035 shares of Repligen at $165.90 each, reducing his stake to 48,369 shares.

Expected impact

Possible modest downside of 1-2% over the next few days.

Evidence & confidence

The sale size (~$0.5M) is modest for a mid-cap, but CEO involvement adds weight; market may react negatively.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector‑wide.

Regional

Limited to U.S. investors tracking Repligen.

Global

Low; the filing does not affect broader markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • Company
    Repligen Corp.

    Biopharmaceutical company (ticker RGEN).

  • Person
    Loeillot Olivier

    Chief Executive Officer of Repligen.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RGEN insider trading history →

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$BLFSHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min